Chapter 2 生物科技

Question 1

Formivirsen

Answer 1

CMV infection Antisense Oligonucleotide

Question 2

Rituximab

Answer 2

B-cell lymphoma CD20 B-cell antigen

Question 3

Alemtuzumab

Answer 3

CLL 淋巴瘤 CD52

Question 4

Trastuzumab

Answer 4

Breast Cancer Her2/neu

Question 5

Cetuximab

Answer 5

多發性上皮癌 EGF Receptor

Question 6

Bevacizumab

Answer 6

乳癌，卵巢癌，肺癌 VEGF 內皮因子

Question 7

Gemtuzumab

Answer 7

AML CD33

Question 8

Denileukin

Answer 8

T-cell 淋巴瘤 interleukin-2 mAb

Question 9

Ibritumomab

Answer 9

B-cell non-hodgkin’s 淋巴瘤 CD28

Question 10

Rituximab

Answer 10

B-cell non-hodgkin’s 淋巴瘤 CD20

Question 11

Nofetumomab

Answer 11

小細胞肺癌 carcinoma antigen

Question 12

Daclizumab

Answer 12

CD25 alpha 防排斥

Question 13

Basiliximab

Answer 13

CD25 alpha + interleukin-2 防排斥

Question 14

Muromonab-CD3 (OKT-3)

Answer 14

T-cell receptor 防排斥

Question 15

Infliximab

Answer 15

IBD Crohn’s Anti-TNF-alpha

Question 16

Adalimumab

Answer 16

IBD, RA Anti-TNF-alpha

Question 17

Efalizumab

Answer 17

psoriasis LFA-1 CD11a

Question 18

Alefacept

Answer 18

psoriasis kymphocytes CD2

Question 19

Abciximab

Answer 19

抗血小板凝集 alphaIIb/betaIII

Question 20

Capromab

Answer 20

Prostrate Cancer prostrate protein

Question 21

Palivizumab

Answer 21

RSV disease RSV antigens

Question 22

Omalizumab

Answer 22

Asthma

Question 23

Southern blotting

Answer 23

DNA sequencing

Question 24

Northern blotting

Answer 24

RNA sequencing

Question 25

Western blotting

Answer 25

Protein complementary antibodies